Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy

Introduction: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse prognosis, however, this group is heterogeneous. Nowadays limited data o...

Full description

Bibliographic Details
Main Authors:	Claudia Omarini, Stefania Bettelli, Samantha Manfredini, Monica Barbolini, Chrystel Isca, Giulia Cortesi, Antonino Maiorana, Giovanni Tazzioli, Massimo Dominici, Federico Piacentini
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Translational Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S193652332030259X

Similar Items

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
by: Chrystel Isca, et al.
Published: (2021-09-01)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
by: Claudia Omarini, et al.
Published: (2020-05-01)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
by: Angela Toss, et al.
Published: (2022-12-01)

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
by: Omarini C, et al.
Published: (2019-11-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
by: Claudia Omarini, et al.
Published: (2020-08-01)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
by: Fabio Canino, et al.
Published: (2022-06-01)

P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial
by: F. Canino, et al.
Published: (2023-03-01)

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients
by: Fabio Canino, et al.
Published: (2024-02-01)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
by: Omarini C, et al.
Published: (2018-01-01)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
by: Krisida Cerma, et al.
Published: (2023-01-01)

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
by: Angela Toss, et al.
Published: (2021-06-01)

The Role of Exosomes in Breast Cancer Diagnosis
by: Claudia Piombino, et al.
Published: (2021-03-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
by: Lucas MW, et al.
Published: (2022-08-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
by: Chrystel Isca, et al.
Published: (2022-12-01)

Deepening the Knowledge of <i>ROS1</i> Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations
by: Giorgia Guaitoli, et al.
Published: (2021-11-01)

Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: María del Pilar Chantada-Vázquez, et al.
Published: (2022-02-01)

Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse
by: Mohammed Ridha Moamin, et al.
Published: (2023-11-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
by: Agnese Fabbri, et al.
Published: (2023-06-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2024-02-01)

The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy
by: Wayne Croft, et al.
Published: (2022-10-01)

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
by: Yasmin Issa-Nummer, et al.
Published: (2013-01-01)

Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
by: Lu Liu, et al.
Published: (2023-12-01)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
by: Hai-long Chen, et al.
Published: (2023-09-01)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
by: Camille Domergue, et al.
Published: (2022-05-01)

P135 Response to neoadjuvant chemotherapy in HER2-positive breast cancers: a single-centre study
by: K. Ben Hamida, et al.
Published: (2023-03-01)

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
by: LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun
Published: (2023-04-01)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
by: de Torraza Idalmis, et al.
Published: (2007-02-01)

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
by: MA Xiangmin, et al.
Published: (2022-01-01)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
by: Ho Hyun Ryu, et al.
Published: (2021-05-01)

ALDH Expression in Angiosarcoma of the Lung: A Potential Marker of Aggressiveness?
by: Beatrice Aramini, et al.
Published: (2020-10-01)

Expression of ALDH and SOX-2 in Pulmonary Sclerosing Pnemocytoma (PSP) of the Lung: Is There a Meaning Behind?
by: Beatrice Aramini, et al.
Published: (2020-09-01)